Guggenheim Maintains Buy Rating and Raises Price Target for First Tracks Biotherapeutics
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on First Tracks Biotherapeutics and increased the price target from $100 to $110.
Stocks · News reference
First Tracks Biotherapeutics Recognized in BioSpace 2027 Best Places to Work List
First Tracks Biotherapeutics was named as one of the top 30 small employers in the life sciences industry in BioSpace's 2027 Best Places to Work list.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Analyst Price Target for First Tracks Biotherapeutics Raised to $75
Analysts have raised the 12-month price target for First Tracks Biotherapeutics to $75, reflecting a potential 62% upside based on recent closing prices.
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics announced that its executive team will participate in several investor conferences throughout November and December 2026.
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Business Update
First Tracks Biotherapeutics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including positive Phase 1b data for ANB033.
8-K filing — First Tracks Biotherapeutics, Inc. (TRAX)
Filed: 2026-11-03 AccNo: 0001193125-26-445405 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
Leerink Partners analyst David Risinger maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $70 to $90.